Compare SWZ & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SWZ | VANI |
|---|---|---|
| Founded | 1986 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.6M | 81.2M |
| IPO Year | N/A | 2014 |
| Metric | SWZ | VANI |
|---|---|---|
| Price | $6.17 | $1.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 14.2K | ★ 173.2K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 6.59% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.12 | $0.91 |
| 52 Week High | $8.57 | $1.92 |
| Indicator | SWZ | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 69.82 | 43.73 |
| Support Level | $6.06 | $1.25 |
| Resistance Level | $6.26 | $1.55 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 80.60 | 33.33 |
Swiss Helvetia Fund Inc is a non-diversified, closed-end investment company. Its investment objective is to seek long-term capital appreciation through investment in equity and equity-linked securities of Swiss companies. The group invests in various sectors such as pharmaceuticals, food and beverage, industrial goods and services, banks, personal and household goods, construction and materials, biotechnology, medical equipment, chemicals, technology, financial services, insurance, Semiconductors, Information Technology, and retail.
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.